Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProMetic human plasminogen intravenous infusion in hypoplasminogenemia
2015-005490-20Phase 2Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plasminogen, human in plasminogen deficiency type 1 (PLGD1), sponsored by Liminal BioSciences Inc. Primary endpoint: Achievement of target plasminogen activity trough levels. Started Apr 2016; status: completed.
02
Drugs
plasminogen, human
03
Conditions
plasminogen deficiency type 1 (PLGD1)
Beyond the preview
Go deeper on 2015-005490-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005490-20.